A Novel Bladder Cancer Surveillance Schedule Using Bladder Cx for Patients on Annual Surveillance

Overview

Journal BJUI Compass

Date 2025 Jan 29

PMID 39877575

Authors

Arjun Guduguntla

Thomas Whish-Wilson

Lauren Chandler

Dennis Gyomber

Affiliations

Soon will be listed here.

Abstract

Objectives: Cx bladder monitor (CxM) is a urine test with a proven high sensitivity and negative predictive value in bladder cancer surveillance. The aim of this retrospective study was to report on the outcomes of our newly implemented bladder cancer surveillance program for patients eligible for yearly cystoscopy, as per the European Association of Urology (EAU) guidelines. In this program, eligible patients alternate between yearly surveillance cystoscopy and CxM, instead of the standard yearly surveillance cystoscopy. Outcomes measures were overall results of CxM and subsequent treatment patterns of patients, impact on waiting lists, cost comparison and patient satisfaction.

Patients And Methods: In 2022, 109 eligible and consenting patients were identified, with 98 commencing on the new surveillance program, starting with CxM instead of cystoscopy. A negative CxM, would result in a planned flexible cystoscopy in 12 months. If a patient had a positive CxM, they proceeded to undergo a cystoscopy, and if required, imaging.

Results: Of the 98 that underwent testing, 90 had a negative CxM test and 8 patients had a positive CxM test. Three of these eight were true positive (PPV 0.375). Seventy negative CxM patients had no recurrence at the time of the next cystoscopy/imaging. Of the remaining 20 negative CxM patients, 11 were found to have a recurrence at subsequent cystoscopy/imaging and 9 did not proceed with further surveillance for various reasons. All of the tumour recurrences diagnosed after a negative CxM were non-invasive, thus there was no progression to muscle-invasive disease. All suitable patients consented to continuing with the CxM protocol. The hospital surveillance cystoscopy waitlist was reduced by approximately 59% and CxM was approximately $850 AUD cheaper than a cystoscopy.

Conclusion: CxM can be safely used in an alternating schedule with Flexible Cystoscopy for patients on annual bladder cancer surveillance.

Citing Articles

A novel bladder cancer surveillance schedule using bladder Cx for patients on annual surveillance.

Guduguntla A, Whish-Wilson T, Chandler L, Gyomber D BJUI Compass. 2025; 6(1):e468.

PMID: 39877575 PMC: 11771502. DOI: 10.1002/bco2.468.

References

de Bekker-Grob E, van der Aa M, Zwarthoff E, Eijkemans M, van Rhijn B, van der Kwast T . Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?. BJU Int. 2009; 104(1):41-7. DOI: 10.1111/j.1464-410X.2008.08323.x. View

Fasulo V, Paciotti M, Lazzeri M, Contieri R, Casale P, Saita A . Xpert Bladder Cancer Monitor May Avoid Cystoscopies in Patients Under "Active Surveillance" for Recurrent Bladder Cancer (BIAS Project): Longitudinal Cohort Study. Front Oncol. 2022; 12:832835. PMC: 8830778. DOI: 10.3389/fonc.2022.832835. View

Babjuk M, Burger M, Capoun O, Cohen D, Comperat E, Dominguez Escrig J . European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2021; 81(1):75-94. DOI: 10.1016/j.eururo.2021.08.010. View

Guduguntla A, Whish-Wilson T, Chandler L, Gyomber D . A novel bladder cancer surveillance schedule using bladder Cx for patients on annual surveillance. BJUI Compass. 2025; 6(1):e468. PMC: 11771502. DOI: 10.1002/bco2.468. View

Sievert K, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M . Economic aspects of bladder cancer: what are the benefits and costs?. World J Urol. 2009; 27(3):295-300. PMC: 2694315. DOI: 10.1007/s00345-009-0395-z. View

Sylvester R, Rodriguez O, Hernandez V, Turturica D, Bauerova L, Bruins H . European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol. 2021; 79(4):480-488. DOI: 10.1016/j.eururo.2020.12.033. View

OSullivan P, Sharples K, Dalphin M, Davidson P, Gilling P, Cambridge L . A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol. 2012; 188(3):741-7. DOI: 10.1016/j.juro.2012.05.003. View

Soukup V, Babjuk M, Bellmunt J, Dalbagni G, Giannarini G, Hakenberg O . Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. Eur Urol. 2012; 62(2):290-302. DOI: 10.1016/j.eururo.2012.05.008. View

Konety B, Shore N, Kader A, Porten S, Daneshmand S, Lough T . Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy. Eur Urol. 2019; 76(2):238-243. DOI: 10.1016/j.eururo.2019.04.035. View

10.

Mossanen M, Gore J . The burden of bladder cancer care: direct and indirect costs. Curr Opin Urol. 2014; 24(5):487-91. DOI: 10.1097/MOU.0000000000000078. View

11.

Herr H . Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol. 1999; 163(1):60-1; discussion 61-2. View

12.

Li K, Chu C, Patel M, Meng M, Morgan T, Porten S . Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer. Urol Oncol. 2023; 41(7):326.e1-326.e8. DOI: 10.1016/j.urolonc.2023.01.009. View

13.

Lotan Y, OSullivan P, Raman J, Shariat S, Kavalieris L, Frampton C . Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urol Oncol. 2017; 35(8):531.e15-531.e22. DOI: 10.1016/j.urolonc.2017.03.008. View

14.

Leal J, Luengo-Fernandez R, Sullivan R, Witjes J . Economic Burden of Bladder Cancer Across the European Union. Eur Urol. 2015; 69(3):438-47. DOI: 10.1016/j.eururo.2015.10.024. View

15.

Holmang S, Strock V . Should follow-up cystoscopy in bacillus Calmette-Guérin-treated patients continue after five tumour-free years?. Eur Urol. 2011; 61(3):503-7. DOI: 10.1016/j.eururo.2011.11.011. View

16.

Kavalieris L, OSullivan P, Frampton C, Guilford P, Darling D, Jacobson E . Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. J Urol. 2016; 197(6):1419-1426. DOI: 10.1016/j.juro.2016.12.010. View

17.

Lough T, Luo Q, OSullivan P, Chemasle C, Stotzer M, Suttie J . Clinical Utility of Cxbladder Monitor for Patients with a History of Urothelial Carcinoma: A Physician-Patient Real-World Clinical Data Analysis. Oncol Ther. 2020; 6(1):73-85. PMC: 7359999. DOI: 10.1007/s40487-018-0059-5. View

18.

Koya M, Osborne S, Chemasle C, Porten S, Schuckman A, Kennedy-Smith A . An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer. BMC Urol. 2020; 20(1):12. PMC: 7014779. DOI: 10.1186/s12894-020-0583-0. View

19.

Koo K, Zubkoff L, Sirovich B, Goodney P, Robertson D, Seigne J . The Burden of Cystoscopic Bladder Cancer Surveillance: Anxiety, Discomfort, and Patient Preferences for Decision Making. Urology. 2017; 108:122-128. PMC: 5626609. DOI: 10.1016/j.urology.2017.07.016. View

20.

Yeung C, Dinh T, Lee J . The health economics of bladder cancer: an updated review of the published literature. Pharmacoeconomics. 2014; 32(11):1093-104. DOI: 10.1007/s40273-014-0194-2. View